目的 探讨芪苈强心胶囊联合左西孟旦注射液治疗扩张型心肌病心力衰竭的临床疗效。方法 选取2019年3月-2020年3月新野县人民医院收治的80例扩张型心肌病心力衰竭患者，根据随机数字表法中数字奇偶法将所有患者分为对照组和治疗组，每组各40例。对照组患者泵注左西孟旦注射液，12 μg/kg，维持10 min后静脉滴注，剂量为0.2 μg/（kg·min），滴注24 h，1次/周。治疗组在对照组治疗的基础上口服芪苈强心胶囊，4粒/次，3次/d。两组患者连续治疗4周。观察两组临床疗效，比较两组的心功能、心肌损伤指标。结果 治疗后，治疗组总有效率（92.50%）高于对照组（72.50%），差异有统计学意义（P<0.05）。治疗后，两组左室射血分数（LVEF）显著升高，左心室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）明显降低（P<0.05），且治疗组LVEF高于对照组，LVESD、LVEDD低于对照组（P<0.05）。治疗后，两组心肌肌钙蛋白I（cTnI）、N末端B型利钠肽原（NT-proBNP）水平均明显降低（P<0.05），且治疗组cTnI、NT-ProBNP水平明显低于对照组（P<0.05）。结论 芪苈强心胶囊联合左西孟旦注射液治疗扩张型心肌病心力衰竭具有较好临床疗效，可提高心功能，减轻心肌损伤，安全性较好。

Objective To explore the effect of Qili Qiangxin Capsules combined with Levosimendan Injection in treatment of dilated cardiomyopathy complicated with heart failure. Methods Patients (80 cases) with dilated cardiomyopathy complicated with heart failure in Xinye County People's Hospital from March 2019 to March 2020 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were pump injection administered with Levosimendan Injection, 12 μg/kg, after 10 min, intravenous drip was administered at a dose of 0.2 g/(kg·min) for 24 h, once weekly. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and cardiac function indexes and myocardial injury indexes in two groups were compared. Results After treatment, the total effective rate of the treatment group (92.50%) was higher than that of the control group (72.50%), and the difference was statistically significant (P<0.05). After treatment, the LVEF of two groups was significantly increased, but the LVESD and the LVEDD were significantly decreased (P<0.05). The LVEF of the treatment group was higher than that of the control group, but the LVESD and the LVEDD of the treatment group were lower than those of the control group (P<0.05). After treatment, the levels of cTnI and NT-Pro BNP in two groups were significantly decreased (P<0.05), and the levels of cTnI and NT-Pro BNP in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qili Qiangxin Capsules combined with Levosimendan Injection has clinical curative effect in treatment of dilated cardiomyopathy complicated with heart failure, can improve cardiac function and reduce myocardial injury.

R972